Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

206

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Atopic Dermatitis

Interventions

DRUG: REGN3500
DRUG: Dupilumab
DRUG: REGN3500 + Dupilumab Combo
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]